News

UK asks for views on safe regulation of new cancer therapies

Date: 03/02/2025     Time: 5:01 PM

The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies (colloquially referred to as cancer vaccines). The eight-week consultation was launched Monday and will run until March 31, 2025. The MHRA is asking all stakeholders, including developers of these medicines, to provide comments, after which the guidance will be updated. The UK regulator also welcomes comments from members of the public, including people affected by cancer. The guidance aims to streamline pathways for bringing these therapies through to patients, without compromising on robust safety principles, noted a government statement.